IP Library Granted Patent US 6,949,527
Granted Patent B2
US 6,949,527 · App. 10/603,355 · Granted Sep 27, 2005

6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,949,527
App. No.
10/603,355
Granted
Sep 27, 2005
Kind
B2
Abstract

Disclosed is a 6-mercapto-cyclodextrin derivative having a general formula (I, ) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C 1-6 ) alkylene, optionally substituted with 1-3 OH groups, or (CH 2 ) o -phenylene-CH 2 ) p —; o and p are independently 0-4; X is COOH, CONHR 3 , NHCOR 2 , SO 2 OH, PO(OH) 2 , O(CH 2 —CH 2 —O) q —H, OH or tetrazol-5-yl: R 2 is H or (C 1-3 )alkyl; R 2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.

Claims (19)

1. A kit for providing neuromuscular block and its reversal comprising (a) an aminosteroidal neuromuscular blocking agent and (b) a reversal agent selected from the group consisting of

6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin;

6-per-deoxy-6-per-(3-carboxypropyl)thio-γ-cyclodextrin;

6-per-deoxy-6-per-(4-carboxyphenyl)thio-γ-cyclodextrin;

6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio-γ-cyclodextrin;

6-per-deoxy-6-per-(2-carboxypropyl)thio-γ-cyclodextrin; and

6-per-deoxy-6-per-(2-sulfoethyl)thio-γ-cyclodextrin;

or a pharmaceutically acceptable salt thereof.

2. A kit according to claim 1 wherein the aminosteroidal neuromuscular blocking agent is selected from the group consisting of rocuronium bromide, vecuronium bromide, pancuronium bromide, and rapacuronium bromide, or another pharmaceutically acceptable salt thereof.

3. A kit according to claim 2 , wherein the neuromuscular blocking agent is rocuronium bromide and the reversal agent is 6-per-deoxy-6per-(2-carboxyethyl)thio-γ-cyclodextrin sodium salt.

4. A method of treatment of a patient with a neuromuscular blocking agent comprising the steps or (a) inducing the neuromuscular block by administration of an effective amount of an aminosteroidal blocking agent selected from the group consisting of rocuronium bromide, vecuronium bromide, pancuronium bromide and rapacuronium bromide, or another pharmaceutically acceptable salt thereof, and (b) reversing the drug-induced neuromuscular block by administration of an effective amount of at least one reversal agent selected from the group consisting of

6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin;

6-per-deoxy-6-per-(3-carboxypropyl)thio-γ-cyclodextrin;

6-per-deoxy-6-per-(4-carboxyphenyl)thio-γ-cyclodextrin;

6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio-γ-cyclodextrin;

6-per-deoxy-6-per-(2-carboxypropyl)thio-γ-cyclodextrin; and

6-per-deoxy-6-per-(2-sulfoethyl)thio-γ-cyclodextrin;

or a pharmaceutically acceptable salt thereof.

5. The method of treatment according to claim 4 , wherein the neuro-muscular blocking agent is rocuronium bromide and the reversal agent is 6-per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin sodium salt.

Assignments (5)
MERGER Recorded Mar 8, 2013
From: ORGANON BIOSCIENCES NEDERLAND B.V.
To: MERCK SHARP & DOHME B.V.
Reel/Frame 029940/0296 →
MERGER Recorded Mar 7, 2013
From: MSD OSS B.V.
To: ORGANON BIOSCIENCES NEDERLAND B.V.
Reel/Frame 029939/0001 →
MERGER Recorded Dec 1, 2011
From: N.V. ORGANON
To: MSD OSS B.V.
Reel/Frame 027307/0482 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2007
From: AKZO NOBEL N.V.
To: N.V. ORGANON
Reel/Frame 018816/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2003
From: ZHANG, MINGGIANG; PALIN, RONALD; BENNETT, DAVID JONATHAN
To: AKZO NOBEL N.V.
Reel/Frame 014239/0354 →